Perspective Therapeutics Inc. (CATX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Perspective Therapeutics Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 2.90 $ — 22% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 345.9% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 14
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.12 | -1.37 – -0.96 | 0 | 19.9% | 8 |
| 12/31/2027 | -1.13 | -1.38 – -0.90 | 1 | -0.8% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.27 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.57 | – | 0 | -30.60 | -17,166.20 | -27 | -41 |
| 2025: Q1 | -0.25 | – | 0 | 5.20 | -5,314.90 | -22 | -26 |
| 2025: Q2 | -0.30 | – | 0 | -44.90 | -7,408.60 | -20 | -21 |
| 2025: Q3 | -0.35 | – | 0 | -43.40 | -12,425.40 | -16 | -18 |
| 2025: Q4 | -0.51 | – | 0 | -81.60 | -87,186.00 | -25 | -30 |
| 2026: Q1 | -25.28 | – | 0 | -77.80 | -34,459.20 | -32 | -38 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 5 | -5 | -5 | -0.09 | -4 | 16 | 18 |
| 2017 | 5 | -6 | -6 | -0.11 | -6 | 11 | 12 |
| 2018 | 7 | -5 | -5 | -0.07 | -5 | 8 | 9 |
| 2019 | 10 | -3 | -3 | -0.05 | -4 | 6 | 9 |
| 2020 | 10 | -3 | -3 | -0.06 | -3 | 13 | 16 |
| 2021 | 11 | -7 | -7 | -0.51 | -8 | 61 | 64 |
| 2022 | 7 | -15 | -15 | -0.27 | -12 | 55 | 58 |
| 2023 | 1 | -41 | -47 | -0.85 | -37 | 75 | 98 |
| 2024 | 1 | 10 | -79 | -1.23 | -18 | 291 | 341 |
| 2025 | 1 | -114 | -103 | -1.40 | -82 | 207 | 267 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Perspective Therapeutics, Inc., ein Unternehmen für radiopharmazeutische Entwicklung, entwickelt und vermarktet präzise zielgerichtete Alpha-Therapien (TAT) zur Krebsbehandlung in den USA.
| Employees | 163 |
|---|---|
| Headquarters | Seattle, WA |
| Address | 2401 Elliott Avenue, 98121 Seattle, United States |
| Phone | 206 676 0900 |
| Website | perspectivetherapeutics.com |
| IPO Date | 10. Nov 2005 |
| ISIN | US46489V3024 |
| Stock Split | 1:10 on 06/17/2024 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Johan M. Spoor | CEO & Director | 1972 |
| Joel David Sendek | CFO & Principal Financial Officer | 1967 |
| Markus Puhlmann M.B.A., M.D. | Chief Medical Officer | 1966 |
| Michael K. Schultz Ph.D. | Co-Founder & Senior Scientific Advisor | – |
| Shane Cobb | Executive Vice President of Operations | – |
| Jonathan R. Hunt | Chief Accounting Officer | 1967 |
| Paul Lyne Ph.D. | Chief Science Officer | – |
| Annie J. Cheng | Vice President of Investor Relations | 1976 |
| Chris Nenno | General Counsel & Corporate Secretary | – |
| Andrew Bright | Executive Vice President of Brachytherapy | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.